New designer drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry

✍ Scribed by Roland F. Staack; Hans H. Maurer

• Publisher: John Wiley and Sons
• Year: 2004
• Tongue: English
• Weight: 147 KB
• Volume: 39
• Category: Article
• ISSN: 1076-5174
• DOI: 10.1002/jms.556

✦ Synopsis

Abstract

Studies are described on the metabolism and toxicological analysis of the piperazine‐derived designer drug 1‐(3,4‐methylenedioxybenzyl)piperazine (MDBP) in rat urine using gas chromatography/mass spectrometry (GC/MS). The identified metabolites indicated that MDBP was metabolized by demethylenation and subsequent methylation to N‐(4‐hydroxy‐3‐methoxybenzyl)piperazine followed by partial glucuronidation or sulfation. Additionally, degradation of the piperazine moiety to N‐(3,4‐methylenedioxybenzyl)ethylenediamine and 3,4‐methylenedioxybenzylamine and N‐dealkylation to piperazine were observed. The authors' systematic toxicological analysis (STA) procedure using full‐scan GC/MS after acid hydrolysis, liquid/liquid extraction and microwave‐assisted acetylation allowed the detection of MDBP and its above‐mentioned metabolites in rat urine after single administration of a dose calculated from the doses commonly taken by drug users. Assuming similar metabolism, the described STA procedure should be suitable for proof of an intake of MDBP by analysis of human urine. Copyright © 2004 John Wiley & Sons, Ltd.